1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,068 | 14:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation | 345 | Business Wire | Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current... ► Artikel lesen | |
| Mi | NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors | 414 | Business Wire | A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third... ► Artikel lesen | |
| 07.04. | A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video | 273 | Business Wire | A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating... ► Artikel lesen | |
| 11.03. | Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan | 464 | Business Wire | €500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening... ► Artikel lesen | |
| 19.02. | NFL Biosciences Publishes Its 2026 Financial Agenda | 361 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda... ► Artikel lesen | |
| 26.01. | NFL Biosciences SA: NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation | 342 | Business Wire | In-depth understanding of the mechanism of action of its drug candidates based on new data Enhanced clinical development strategy based on these advances, targeting clinical efficiencies... ► Artikel lesen | |
| 08.12.25 | NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application | 300 | Business Wire | These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners New patent application currently in preparation Results... ► Artikel lesen | |
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | NFL Biosciences SA: NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners | 388 | Business Wire | Regulatory News:
NFL Biosciences SA (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents... ► Artikel lesen | |
| 20.10.25 | NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA | 469 | Business Wire | Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO... ► Artikel lesen | |
| 16.10.25 | NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development | 523 | Business Wire | Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions... ► Artikel lesen | |
| 01.09.25 | NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT) | 784 | Business Wire | The SRNT, the world's leading scientific society dedicated to nicotine and tobacco research, publishes the results of the CESTO II study in its reference journal, thereby ensuring their optimal... ► Artikel lesen | |
| 28.07.25 | NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101 | 407 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces... ► Artikel lesen | |
| 22.07.25 | NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction | 402 | Business Wire | A €600,000 "Innovation Advance" repayable advance granted by Bpifrance
€600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 11,010 | 0,00 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| KAILERA THERAPEUTICS | 26,010 | 0,00 % | Heißes Adipositas-IPO: Kailera will es mit den Großen aufnehmen | Der wachstumsstarke Markt für Appetitzügler ist heiß umkämpft. Immer mehr Player streben in den Markt, um sich mittel- bis langfristig ein Stück vom milliardenschweren Kuchen abzuschneiden. Auch Kailera... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 22,460 | 0,00 % | Qiming Venture Partners: Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ | SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 342,50 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | 0,00 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| SUMMIT THERAPEUTICS | 25,140 | 0,00 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| CG ONCOLOGY | 73,44 | 0,00 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| BIONTECH | 86,70 | -0,86 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| ERASCA | 18,995 | 0,00 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| IMMUNOVANT | 29,300 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CABALETTA BIO | 3,440 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PSYENCE BIOMEDICAL | 7,590 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,340 | 0,00 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential | ||
| APOGEE THERAPEUTICS | 92,12 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
NFL BIOSCIENCES SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,961 Euro und damit -4,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.